{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:02:42Z","timestamp":1771956162595,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/md.0000000000007145","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T10:23:45Z","timestamp":1498040625000},"page":"e7145","source":"Crossref","is-referenced-by-count":27,"title":["Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis"],"prefix":"10.1097","volume":"96","author":[{"given":"Zeren","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210226","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00296-008-0743-0","article-title":"Clinical features of ankylosing spondylitis may correlate with HLA-B27 polymorphism","volume":"29","author":"Zhen","year":"2009","journal-title":"Rheumatol Int"},{"key":"R2-17-20210226","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","article-title":"The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States","volume":"345","author":"Reveille","year":"2013","journal-title":"Am J Med Sci"},{"key":"R3-17-20210226","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R4-17-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clineuro.2015.10.014","article-title":"Management of spinal fractures in patients with ankylosing spondylitis","volume":"139","author":"El Tecle","year":"2015","journal-title":"Clin Neurol Neurosur"},{"key":"R5-17-20210226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.2016.1116519","article-title":"An overview of investigational new drugs for treating ankylosing spondylitis","volume":"25","author":"Wendling","year":"2015","journal-title":"Expert Opin Inv Drug"},{"key":"R6-17-20210226","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3906\/sag-1401-79","article-title":"Treatment of ankylosing spondylitis","volume":"45","author":"Sari","year":"2015","journal-title":"Turk J Med Sci"},{"key":"R7-17-20210226","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"R8-17-20210226","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis\u2014art. no. CD004800.pub2","volume":"11","author":"Chen","year":"2005","journal-title":"Cochrane Db Syst Rev"},{"key":"R9-17-20210226","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpba.2007.10.038","article-title":"Drug safety, drug quality, drug analysis","volume":"48","author":"G\u00f6r\u00f6g","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"R10-17-20210226","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14740338.2016.1160054","article-title":"The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis","volume":"15","author":"Hern\u00e1ndez","year":"2016","journal-title":"Exp Opin Drug Safety"},{"key":"R11-17-20210226","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"J\u00dcRgen Braun","year":"1995","journal-title":"Arthritis Rheumatol"},{"key":"R12-17-20210226","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2005.037465","article-title":"Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases","volume":"65","author":"Fran\u00e7ois","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R13-17-20210226","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"R14-17-20210226","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis via tumor necrosis factor-alpha inhibition","volume":"346","author":"Higuchi","year":"2002","journal-title":"New Engl J Med"},{"key":"R15-17-20210226","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"R16-17-20210226","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis","volume":"33","author":"Machado","year":"2013","journal-title":"Rheumatol Int"},{"key":"R17-17-20210226","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"R18-17-20210226","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R19-17-20210226","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"D\u00e9sir\u00e9e van der Heijde","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"R20-17-20210226","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"R21-17-20210226","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50\u200amg once weekly is as effective as 25\u200amg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R22-17-20210226","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"R23-17-20210226","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R24-17-20210226","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R25-17-20210226","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61","author":"Sieper","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R26-17-20210226","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R27-17-20210226","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"Embo j"},{"key":"R28-17-20210226","doi-asserted-by":"crossref","first-page":"R189","DOI":"10.1186\/ar4379","article-title":"A complex interaction between Wnt signaling and TNF-alpha in nucleus pulposus cells","volume":"15","author":"Hiyama","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R29-17-20210226","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","article-title":"High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis","volume":"71","author":"Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R30-17-20210226","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ng.1005","article-title":"A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis","volume":"44","author":"Lin","year":"2012","journal-title":"Nat Genet"},{"key":"R31-17-20210226","first-page":"1","article-title":"An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis","volume":"10","author":"Osman","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"R32-17-20210226","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti\u2013tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R33-17-20210226","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"A human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R34-17-20210226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"New Engl J Med"},{"key":"R35-17-20210226","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor \u03b1 agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R36-17-20210226","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"R37-17-20210226","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R38-17-20210226","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2147\/PPA.S33109","article-title":"Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis","volume":"7","author":"Senabre-Gallego","year":"2013","journal-title":"Patient Preference Adherence"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:51:53Z","timestamp":1620960713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201706230-00017"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":38,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007145","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}